Real world evidence from the world’s largest prospective,1,2 phase IV study of Ozurdex (dexamethasone) intravitreal implant in patients with diabetic macular oedema (DME) showed improved outcomes across two patient populations: in the first-line setting, as well as those refractory to anti- VEGF treatment.1,2
The study, involving 200 patients with vision loss due to DME, showed Ozurdex significantly improved both best-corrected visual acuity (BCVA) and central macular thickness (CMT) at 12 months for the 55 treatment-naive patients (P=0.042 and P<0.001, respectively).1 In this arm of the study, not only did treatment with Ozurdex meet both of its primary endpoints, significant improvements were demonstrated as early as week six for both BCVA and CMT.1 For the 142 patients refractory to anti- VEGF treatment, Ozurdex significantly improved CMT at 12 months (P<0.001), and mean change in BCVA was significantly improved at weeks six and 24 (P<0.001).2
Contact: Allergan (AUS) 1800 252 224
References:
- Fraser-Bell S et al. Dexamethasone Intravitreal Implant in Treatment-Naïve Diabetic Macular Edema – Findings from the Prospective, Multicenter, AUSSIEDEX Study. Presented at EURETINA, 06 Sep 2019, Paris, France.
- Arnold J et al. Dexamethasone Intravitreal Implant in Diabetic Macular Edema Refractory to Anti-Vascular Endothelial Growth Factor Therapy – A Subgroup Analysis of the Phase 4, Open-label, Non-randomized, Prospective AUSSIEDEX Study. Presented at EURETINA, 06 Sep 2019, Paris, France.
